





Breast Pathology




Terminal ductulo-lobular unit (TDLU)




Terminal ductulo-lobular unit (TDLU)

Ductal Anatomy




Epithelial cells: CK 19 +, CK7+, CK8/18+
Myoepithelial cells: calponin+, p63, CK14+, CK5+




Normal breast


Breast Anatomy



Anatomy of the Female Breast





An acinus (circled in black) is an epithelial substructure found in lobules.




© 2012 Terese Winslow LLC,
U.S. Govt. has certain rights

Courtesy of the Susan G. Komen Tissue Bank
at the IU Simon Cancer Center
(www.virtualtissuebank.iu.edu)



Normal breast





Normal breast



Normal breast – myoepithelial cells



Normal breast – lactation changes



Breast pathology

- Very frequent
- Fertile women (35-55 ys.)
- Neoplastic and non-neoplastic
- Increasingly detected by screening
- Increasingly curable
- Interdisciplinary approach needed

Breast pathology

- Inflammatory (mastitis)
 - Relatively rare
 - Young women
 - Post-gravidic / breast-feeding
 - Post-traumatic
 - Symptomatic (tension, pain, red discoloration)

Breast pathology

- Mastitis
 - Acute, non-specific (mucous-purulent)
 - Nipple ulceration, fissuration
 - Ascending, canalicular
 - Abscess formation
 - Peri- and/or intra-ductal exudate
 - Possible fibrotic evolution

PERIDUCTAL MASTITIS

Extralobular ducts lesion:

Variably sized cysts

Cubic-flat epithelial lining

No apocrine metaplasia

Foamy macrophages and amorphous debris

Periductal inflammation


Calcifications

Fibrosis


Histiocytes


Plasmacells

Giant cells




Residual duct
Inflammatory cells
Necrotic debris
Normal duct






Obliterative mastitis: completely obstructed duct with fibrous plaque



Lobular inflammatory infiltration (lymphocytes)

Breast pathology

- Mastitis
 - Plasma cell mastitis
 - Monolateral
 - Perimenopausal
 - Sub-acute / chronic
 - Periductal plasma cell infiltration
 - Ductal epithelial proliferation



Breast pathology

- Mastitis

- Tuberculous mastitis

- Yaoung women, pregnant

- During secondary (post-primary) TB

- Miliar, nodular, cold abscess, galactophoritis

- Caseating granulomas

- Reactive axillary lymphadenitis

Breast pathology

- Mastitis

- Liponecrosis & lipogranulomatosis

- Mature/older women

- Post-traumatic or post-operative



- Sub-acute, chronic

- Areolar or sub-areolar


- Fibrous, poorly demarcated plaque

- Foamy macrophages, foreign body giant cells

Liponecrosis/granulomatosis



Liponecrosis/granulomatosis



Breast pathology

- Breast neoplasms
 - Real increase in west countries
 - Favoured by reduced breast-feeding
 - Increasingly detected by screening
 - Associated with hyper-oestrogenism
 - Rare in hereditary conditions (BRCA1-BRCA2)


Breast neoplasms

- Breast tumour diagnosis
 - Clinical-radio-pathologic correlations
 - Sub-centimetric lesions identified
 - Non-nodular lesions
 - Micro-calcifications
 - Parenchymal “*distorsions*”
 - Usually asymptomatic

Breast neoplasms

- Screening
 - Suggested between 25-30 ys. (earlier with familiarity)
 - Age-related
 - Visit
 - U.S. (younger than 40 ys.)
 - Mammography (older than 40 ys.)
 - Annual/biennial (in healthy women)

Breast neoplasms



Breast neoplasms

- Screening

- Mini-invasive sampling


- Fine-needle aspiration biopsy (≥ 1 cm nodules)

- Tru-cut (Parenchymal distortions, neo-adjuvant tx)

- Mammotome (microcalcifications)


TYPE 1 MICROCALCIFICATIONS

Calcium oxalate, non-tingible, bi-rifrangent under polarized light, associated with benign lesions




TYPE 2 MICROCALCIFICATIONS

Calcium phosphate,
basophilic, non
birifrangent



Associated with
both benign and
malignant lesions



Clinico-pathological correlations

SOLID NODULES

Fibroadenoma
Phyllodes tumour
Adenoma
 Tubular
 Ductal (nipple)
 Lactating
 Pleomorphic
Adenosis tumour

CYSTIC NODULES

Solitary cyst
Duct ectasia
Intraductal papilloma
Fibrocystic disease

NON DEMARCATED LESIONS


Fibroadenomatous hyperplasia
Sclerosing lobular hyperplasia

SOLITARY CYST

Diameter > 10mm

Flat epithelial lining

Apocrine changes, scattered papillary projections



Fibrocystic disease

Very frequent, young women

- Dense breasts
- Bilateral
- Cysts and parenchymal distortions
- Cyclic modifications (peri-menstrual)
- Painful tension (mastodinia)

Unrelated to breast cancer!

Fibrocystic disease

Non-proliferative changes


- Inflammation
- Fibrosis
- Duct ectasia/cysts
- Apocrine changes


Proliferative changes

- Adenosis (acinar/lobular proliferation)
- Epitheliosis (ductal epithelial proliferation)
- Papillomatosis (intra-ductal projections)


Fibrocystic disease

Early lobular changes, progressive dilation, cyst formation, apocrine changes






Apocrine changes




Fibrocystic disease

Papillary projections



Fibrocystic disease

Microcalcifications



Fibrocystic disease

Hyperplastic changes

Adenosis (increased acini within ductules)


- Florid
- Sclerosing
- Blunt duct
- Microglandular
- Pseudo-tumoral (adenosis tumour)
 - Ductular proliferation
 - Epithelial + myoepithelial cells (not in microglandular)
 - Virtual or cystic lumina
 - Possible evolution in radial scar


ADENOSIS

Increased number of acini with lobular expansion

Sclectosing adenosis

- Architectural distorsion
- Acinar distension
- Increased collagen stroma
- Central sclerotic focus
- Myoepithelial hyperplasia
- Pseudoinfiltration
- Microcalcifications
- Apocrine metaplasia
- No cytologic atypia







MICROGLANDULAR ADENOSIS

No lobular growth pattern

- Glandular structures with monolayered epithelium
- Pseudoinfiltrative growth in fat tissue
- No myoepithelial cells
- Endoluminal secretion
- Rare atypia or mitosis
- Clear cells







APOCRINE ADENOSIS

Apocrine cell change without cystic dilation

GCDFP + (Gross cystic Disease Fluid Protein)




Radial (sclero-elastotic) scar

Small ducto-lobular structures, radiating from central fibrotic core:


- Circumscribed nodular lesion
- Starry configuration
- < 10mm
- Elongated central tubules
- Epiteliosis & adenosis
- Myoepithelial cells
- Microcalcifications


Radial (sclero-elastotic) scar




The lesion seem to develop from peripheral tubular proliferation around obstructed ducts

Radial (sclero-elastotic) scar








FIBROADENOMA

- Young women (15-25)
- Well-demarcated nodule/s
- Monolaterale, 20% bilateral
- ≤ 3 cm
- Fibro-elastic consistency
- Calcifications (pop-corn like)

FIBROADENOMA

Fibrous connective tissue


Intracanalicular






Focal fibrous proliferation compressing the enclosed glandular structures


Glandular structures

Pericanicular



Ductular proliferation with preserved rounded profile, and concentric fibrous stroma





FIBROADENOMA

Epithelial tissue:

- Double layered (epithelium & myoepithelium)
- Adenosis & epitheliosis
- In older lesions →

- Hyalinization
- Calcification
- Ossification
- Chondroid metaplasia
- Epithelial atrophy

Caveat!




No risk of progression


Atypical hyperplasia & carcinoma in situ may coexist


FIBROADENOMA


Connective tissue metaplasia

Fibrous
Adipose
Smooth muscle
Bone










JUVENILE FIBROADENOMA


- Very young patients (<20 ys)
- Larger size (>3 cm)
- Mostly pericanalicular
- Hypercellular myxoid stroma

TUBULAR ADENOMA

- Continuum with fibroadenoma
- Less frequent
- Fibro-elastic
- ≤ 4 cm
- Balanced fibro-epithelial proliferation
- Compact tubules with myoepithelial cells
- Eosinophilic secretion
- Mitotically active






- Extensive apocrine metaplasia
Apocrine Adenoma
- Extensive secretory component
Lactating Adenoma



PHYLLODES TUMOUR

- Rapidly growing, well-demarcated nodule
- Larger size (≥ 5 cm)
- Older age (>35 ys)
- More aggressive behaviour, depending on Grade




PHYLLODES TUMOUR


- Bosselated surface
- Fleshy appearance
- Possibly infiltrative margins



PHYLLODES TUMOUR



PHYLLODES TUMOUR (BENIGN 60%)




PHYLLODES TUMOUR

LOW GRADE MALIGNANT 20%






Increased stromal cellularity
Rare mitotic figures
No cytologic atypia
Increased recurrence rate

HIGH GRADE MALIGNANT 20%




Sarcomatous stroma
Nuclear pleomorphism
Mitotically active (10/10HPF)
Heterologous differentiation
Frequent recurrences
Rare distant metastases



DUCTAL ADENOMA


Glandular proliferation with adenomatous and papillary growth patterns

May develop marked fibrotic proliferation, simulating a radial scar




NIPPLE ADENOMA



- Rare
- 40-50 ys.
- Blood discharge
- Nipple enlargement
- Skin erosion
- Simulates Paget's disease



INTRADUCTAL PAPILOMA



a



b

c

INTRADUCTAL PAPILLOMA

SOLITARY: central, larger, lactiferous ducts

MULTIPLE: peripheral, smaller, TDLU

Branching fibrovascular core

Epithelial & myoepithelial cells

Apocrine or squamous metaplasia

Periductal fibrosis

Pseudo-infiltrative margins

Epithelial hyperplasia \pm atypia

May progress into papillary carcinoma (decades)




INTRADUCTAL PAPILLOMA





Papilloma


Benign Intraductal Papilloma


Copyright © 2007 Lippincott Williams & Wilkins. Subscribers Receive CD-ROM to Accompany *Stable's Atlas of Physical Examination and History Taking*, sixth edition.













Ductal papilloma: apocrine metaplasia





Metaplasia squamosa

HYPERPLASIA

Epithelial intra-luminal proliferation

Isolated or in association with benign (fibroadenoma, fibrocystic disease, etc.) or malignant (invasive carcinoma) lesions

- **DUCTAL**: Interlobular ducts
- **LOBULAR**: TDLU

HYPERPLASIA

- **USUAL:** Increased cell number with no nuclear/architectural alterations
- **ATYPICAL:** Bland nuclear/architectural alterations
 - Columnar cell alterations
 - Atypical cystic nodules
 - Clinging (in situ) carcinoma
- **CARCINOMA IN SITU:** Frank nuclear/architectural alterations
 - Within the basal lamina
 - 3-tiered grading system


USUAL HYPERPLASIA


DUCTAL


- Predominantly epithelial cells
- Elongated cells
- Nuclear streaming
- Normochromic , angulated/spindle nuclei
- Bland chromocenters
- **Plump myoepithelial cells**
- Polymorphic fenestrations
- Rare mitosis, no necrosis

LOBULAR

- Partial obliteration of acinar lumina
- No more than 4 cell layers
- **Myoepithelial cells recognizable**







ATYPICAL DUCTAL HYPERPLASIA / CARCINOMA IN SITU

- Increasingly detected by screening
- Morphologically heterogeneous lesions
- Poor inter-observer reproducibility (ADH vs. low grade DCIS)
- Different risk for progression towards invasive carcinoma
- Risk of over-treatment
- Distinct molecular alterations (LOH)
- Psychologic impact of “carcinoma”

ADH / DCIS

Cytological features

- Monotonous and uniform cells
- Increased N/C ratio
- Rosette-like formations
- Rounding and “standing” nuclei
- Nuclear hyperchromasia
- Mitosis & necrosis rare

Architectural features

- Limited extension ($\leq 2\text{mm}$)
- Scattered ductal structures
- Bridging
- Cribriform, micro-papillary

The D.I.N. (Ductal Intra-epithelial Neoplasia) concept

- Standardized diagnostic criteria
- Increased inter-observer agreement
- Progressively increasing risk
- Avoiding the term “carcinoma”
- Closer to other **Grading** systems

DIN 1-2-3

Traditional terminology	DIN terminology
Usual ductal hyperplasia	Usual ductal hyperplasia (UDH)
Flat epithelial atypia	DIN Grade 1a
Atypical ductal hyperplasia (ADH)	DIN Grade 1b
Ductal carcinoma in situ (DCIS) low grade	DIN Grade 1c
Ductal carcinoma in situ (DCIS) intermediate grade	DIN Grade 2
Ductal carcinoma in situ (DCIS) high grade	DIN Grade 3


FLAT EPITHELIAL ATYPIA = DIN 1a



- Hyperplastic lesions (not filling the lumen)
- Minimal:
 - architectural distortion
 - nuclear pleomorphism
- Low risk of association with invasive cancer
- 3 major morphological presentations:
 - Columnar cell lesions
 - Clinging carcinoma
 - Atypical cystic lobules

FLAT EPITHELIAL ATYPIA = DIN 1a COLUMNAR CELL LESIONS

Columnar cells with abundant cytoplasm
Apical vesicles (snouts)
Hobnail morphology
Intraluminal secretion
Bridges & micropapillae
Polistratification
Microcalcifications


Nuclear atypia may be present
(tubular) carcinoma may coexist






FLAT EPITHELIAL ATYPIA = DIN 1a CLINGING CARCINOMA

Flat cells with scarce cytoplasm
Nuclear hyperchromasia
Intraluminal secretion
Polistratification
Microcalcifications



FLAT EPITHELIAL ATYPIA = DIN 1a ATYPICAL CYSTIC LOBULES


Enlarged lobular architecture
Hypercellular lobules
Cystic spaces
Columnar cell morphology
Intraluminal secretion
Polistratification
Microcalcifications




ATYPICAL DUCTAL HYPERPLASIA = DIN 1b

- Hyperplastic lesions growing within the lumen
- **Minimal:**
 - extension (≤ 2 mm.)
 - architectural distortion
 - nuclear pleomorphism
- Low risk of association with invasive cancer


MORPHOLOGICAL BREAST CHANGES FROM NORMAL TO INVASIVE CANCER




MORPHOLOGICAL BREAST CHANGES FROM NORMAL TO INVASIVE CANCER



ATYPICAL DUCTAL HYPERPLASIA = DIN 1b




Usual ductal hyperplasia



Atypical ductal hyperplasia
DIN 1b

ATYPICAL DUCTAL HYPERPLASIA = DIN 1b




DUCTAL CARCINOMA IN SITU = DIN 1c-3

- Neoplastic lesions extensively growing within the lumen
- **Increased:**
 - extension (≥ 2 mm.)
 - architectural distortion
 - nuclear pleomorphism
- Higher risk of **recurrence** (DCIS)
- Higher risk of **association** with **invasive cancer**

DUCTAL CARCINOMA IN SITU = DCIS 1c-3

10-Year Risk of Local Recurrence, Based on DCIS score



DUCTAL CARCINOMA IN SITU = DIN 1c-3

RESULTS

DCIS Score = 19





Figure 3: Using the DCIS Score to Determine 10-Year Risk Estimates for an Ipsilateral Breast Event (left) and Invasive Breast Cancer (right)—CI = confidence interval; DCIS = ductal carcinoma in situ.

PROGRESSION TO CANCER = OLD


Progression of BC (IDC) at the level of histological lesions



Usual type ductal hyperplasia does not progress into atypical ductal hyperplasia.

PROGRESSION TO CANCER = NEW


Progression of BC (IDC) at the level of histological lesions




Low-grade pathway

High-grade pathway


PROGRESSION TO CANCER = NEW



Well differentiated DCIS – DIN 1c




Well differentiated DCIS – DIN 1c with microcalcifications




Well differentiated DCIS – DIN 1c
with micropapillae (a) or cribriform
pattern (b)


a




c




b



Moderately differentiated DCIS – DIN 2 with microcalcifications and necrosis



Poorly differentiated DCIS – DIN 3 with microcalcifications, necrosis and nuclear pleomorphism



LOBULAR HYPERPLASTIC LESIONS

USUAL


Non-distended acini, partly or completely filled with monomorphic cells

ATYPICAL

Poorly distended acini, filled with poorly cohesive monomorphic cells; partial or complete lobular involvement

LOBULAR CARCINOMA IN SITU

Severely distended acini, filled with cells that may be pleomorphic; possible confluence of adjacent acini; expansion of lobules



LIN 1-2-3

Traditional terminology	LIN terminology
Usual lobular hyperplasia	Usual lobular hyperplasia (ULH)
Atypical lobular hyperplasia	LIN Grade 1
Lobular carcinoma in situ (LCIS) low grade	LIN Grade 2
Lobular carcinoma in situ (LCIS) high grade	DIN Grade 3

LIN 1-2-3


^ Figure and tables index

Next table >

	LIN, grade 1	LIN, grade 2	LIN, grade 3
Loosely cohesive cellular proliferation	+	+	+
Preserving distinct ductular outlines	+	+	- (Virtual confluence)
Filling the acinar space	±	+	+
Acinar distension	-	+	+++ (Maximally)
Nuclear pleomorphism ^a	-	-	Rarely
Pure classic signet ring cell population ^a	-	-	Rarely

LIN, lobular intraepithelial neoplasia.

^a If present, maximum distension of acini is not required.



Relationship between lobular intraepithelial neoplasia and invasive lobular carcinoma. The increasing grade of lobular intraepithelial neoplasia directly correlates with association of invasive lobular carcinoma ($P=0.01$).


LCIS facts

- 25% of all CIS
- Frequently multicentric/bilateral
- ILC in 20-30% (life-time)
- No palpable mass (biopsy incidental finding)
- Better detected by US


Management:

- Clinical + US follow-up (4 mo.)
- Mammography (yearly)
- Chemoprevention (anti-hormonal tx)
- Consider surgery for LIN3 and larger lesions

DUCTAL vs. LOBULAR HYPERPLASIA




Ductal




Lobular


Lobular carcinoma in situ




Usual & atypical lobular hyperplasia = LIN1




Lobular carcinoma in situ, low grade = LIN2





Lobular carcinoma in situ, low grade = LIN2





Lobular carcinoma in situ, high grade = LIN3



Lobular carcinoma in situ, high grade = LIN3






a

b

Fig. 40 - a) Neoplasia lobulare classica con acini espansi da cellule regolari. b) Neoplasia lobulare con cellule negative per *cadherina e*. c) Diffusione Pagetoide: le cellule della neoplasia lobulare, negative per *cadherina e*, si insinuano tra il mioepitelio e l'epitelio secretorio del lume. Queste ultime si riconoscono in quanto conservano la colorazione della membrana cellulare per *cadherina e*.



c

Paget's disease of the nipple

Erosive-ulcerative lesion

Mature-older patients

Blood nipple discharge

Intra-epidermal neoplastic epithelial cells

Her2-positive



Frequent DCIS in lactiferous ducts

Similar to vulvar Paget's disease


Paget's disease of the nipple



Paget's disease of the nipple



© Muir's Textbook of Pathology, 14th edition,




Her2

INVASIVE BREAST CARCINOMA

- Most frequent cancer in women
- 22% of all malignant neoplasms in women ($\leq 1\%$ in men)
- 6-8% of women develop breast cancer
- 1st cause of cancer-related death in women
- Up to 33% cancer-specific mortality
- Increasing incidence, decreasing mortality in western countries

INVASIVE BREAST CARCINOMA



INVASIVE BREAST CARCINOMA

Predisposing factors:

- Geographical: industrialization, breast-feeding, hypercaloric diet, alcohol intake, low physical activity
- Early menarch (< 12 ys)
- Late menopause (> 54 ys)
- Nulliparity
- Late pregnancy
- Short (< 3 mo.)/no breast-feeding
- Familiarity (mother & sisters)
- Obesity (BMI >25Kg/mq)
- Genetic factors: BRCA1 (17q), BRCA2 (12q12-13)
- Irradiation (Hiroshima, radiotherapy)

INVASIVE BREAST CARCINOMA

Risk factors:

Personal:


- Previous breast cancer (invasive >> in situ)
- Previous DIN/LIN
- Ductal papilloma
- Ovarian / endometrial cancer

Familial: mother or sisters with breast cancer


Li-Fraumeni syndrome

BRCA1 or BRCA2 syndrome

INVASIVE BREAST CARCINOMA



INVASIVE BREAST CARCINOMA



INVASIVE BREAST CARCINOMA

Role of oestrogens:

- Bind to specific nuclear receptors
- Induce specific proliferative effects
- Accentuated in obese and persistent in menopause
- Genotoxic direct effect, mediated by P450 (increased free radicals)
- Phytoestrogens (pesticides, biphenyl-poly-chlorurates) accumulates in breast adipose tissue
- Hormone replacement therapy in menopause
- Oral contraceptive?

SYNDROMIC BREAST CARCINOMA

Li-Fraumeni

- Constitutive mutation of p53
- Multiple neoplasms at < 30 ys.
- Breast cancer at < 40 ys.
- Osteosarcoma
- Soft tissue sarcomas at < 45 ys.
- Brain tumours
- Leukemia

BRCA1

- Constitutive mutation of BRCA1 (17q21)
- Juvenile ovarian or breast cancer
 - No previous DIN/LIN
 - ER & PgR negative
 - Her2 negative
- Additional carcinomas (colon, liver, endometrium, cervix)
- Prophylactic surgery
- Chemoprevention (Tamoxifen)

BRCA2

- Constitutive mutation of BRCA2 (13q12-13)
- Juvenile ovarian or breast cancer
 - DCIS
 - ER & PgR positive
 - Additional cancers (ovary, salpynx, pancreas, gallbladder)
- Melanoma
- Prophylactic surgery
- Chemoprevention (Tamoxifen)

HEREDITARY BREAST CARCINOMA


- BRCA1 & 2 in 80% hereditary breast cancers
- 6-10% of all breast cancers

Molecular screening:

- In high risk patients
- Identification of 1st case
- High cost
- Complex techniques
- Germline mutations
- No cost/effective

INVASIVE BREAST CARCINOMA

- Maximal prevalence: > 45 ys.
- More frequently asymptomatic
- Site: >50 % in UEQ
- Firm nodule with stellate borders
- Skin or nipple retraction = late events
- Association with pre-neoplastic lesions:
 - Carcinoma in situ (DIN or LIN)
 - Ductal papilloma



FNAB: palpable nodules

C1. inadequate

C2. benign lesion

C3. possibly benign lesion

C4. possibly malignant lesion

C5. malignant

Core biopsy & mammotome: non-palpable lesions and microcalcifications


B1. normal

B2. benign lesion


B3. uncertain malignant potential

B4. possibly malignant lesion

B5. malignant




sede




How dense are you?

LEVEL 1




<25% Density
Fatty Breast Tissue

LEVEL 2




<50% Density
Scattered Density

LEVEL 3





>50% Density
Heterogeneously Dense


LEVEL 4



>75% Density
Extremely Dense







INVASIVE BREAST CARCINOMA PROGNOSTIC FACTORS

Patient characteristics

Age
(Race)

Disease characteristics

Tumor **size**
Tumor type
Tumor **grade**
Axillary lymph node status
Peritumoral vascular invasion

Biomarkers

Receptor status (ER, PgR)
HER2 expression
Ki-67 labeling index

Genetic profile (!)

Mammaprint
OncotypeDx
PAM50

INVASIVE BREAST CARCINOMA

Main histotypes:

- Ductal (70%)
- Lobular (20%)
- Special types (10%)

Good prognosis:

- Tubular
- Cribriform
- Mucinous
- Papillary
- Adenoid-cystic
- Lobular (classic) G1
- Medullary

Poor prognosis:


- Extensive central necrosis
- Extensive central fibrosis
- Lobular (pleomorphic) G3
- Matrix-producing
- Metaplastic
- Micropapillary
- Apocrine

St. Gallen


Endocrine-responsiveness

Highly responsive	Incompletely responsive	Non-responsive
<ul style="list-style-type: none">• High ER & PgR <p><i><u>and</u></i></p> <ul style="list-style-type: none">• Low Ki-67 <p><i><u>and</u></i></p> <ul style="list-style-type: none">• No HER2 overexpr.	<ul style="list-style-type: none">• Low ER & PgR <p><i><u>or</u></i></p> <ul style="list-style-type: none">• PgR absent <p><i><u>or</u></i></p> <ul style="list-style-type: none">• HER2 overexpr <p><i><u>or</u></i></p> <ul style="list-style-type: none">• High Ki-67	<ul style="list-style-type: none">• ER & PgR <p>both absent</p>


INVASIVE BREAST CARCINOMA




Invasive (infiltrating) ductal carcinoma




Invasive (infiltrating) ductal carcinoma



Invasive (infiltrating) lobular carcinoma



Invasive (infiltrating) lobular carcinoma








Fig. 49 – a) Carcinoma tubulare frammiato a CDIS ben differenziato. b) Tipico tubulo mostrandente una sola fila di cellule.




Cribriform in situ and invasive ca.




Adenoid-cystic carcinoma


Matrix-producing carcinoma




Micropapillary carcinoma



Mucinous carcinoma



a



b


Present or future?

Gene expression profiling predicts clinical outcome of breast cancer


Laura J. van 't Veer^{*†}, Hongyue Dai^{†‡}, Marc J. van de Vijver^{*†}, Yudong D. He[‡], Augustinus A. M. Hart^{*}, Mao Mao[‡], Hans L. Peterse^{*}, Karin van der Kooy^{*}, Matthew J. Marton[‡], Anke T. Witteveen^{*}, George J. Schreiber[‡], Ron M. Kerkhoven^{*}, Chris Roberts[‡], Peter S. Linsley[‡], René Bernards^{*} & Stephen H. Friend[‡]

^{*} Divisions of Diagnostic Oncology, Radiotherapy and Molecular Carcinogenesis and Center for Biomedical Genetics, The Netherlands Cancer Institute, 121 Plesmanlaan, 1066 CX Amsterdam, The Netherlands
[†] Rosetta Inpharmatics, 12040 115th Avenue NE, Kirkland, Washington 98034, USA

NATURE | VOL 415 | 31 JANUARY 2002 | www.nature.com




Present or future?




microarray

Gene-expression profile



N Engl J Med, Vol 347 (25), Dec. 2002

N Engl J Med. 2002 Dec 19;347(25):1999-2009



LUMINAL A
LUMINAL B
ERBB2+
BASAL LIKE
NORMAL BREAST

Molecular apocrine
Claudin-low

INVASIVE BREAST CANCER PROGRESSION

- Recurrence (ipsi-controlateral)
- Lymphatic invasion
 - Axillary or internal mammary nodes
- Haematogenous dissemination (lung, liver, bone, CNS, adrenal)
- Contiguity dissemination (pleura)
- Ovarian colonization

INVASIVE BREAST CANCER PROGRESSION

OVERALL SURVIVAL

5 ys.: St. I = 80%, St. II = 65%, St. III = 40%, St. IV = 10%

30 ys.:

- DCIS: 74%
- Papillary: 65%
- Medullary: 58%
- Ductal: 34%
- Lobular: 29%


INVASIVE BREAST CANCER PROGRESSION

Stage	5-year Relative Survival Rate
0	100%
I	100%
IIA	92%
IIB	81%
IIIA	67%
IIIB	54%
IV	20%

Table 2-1 - Breast cancer mortality rate by stage. Source: American Cancer Society

INVASIVE BREAST CANCER PROGRESSION

Figure 3.3: Ten-year relative survival rate, female breast cancer, England and Wales, 1971-2000



* England only

INVASIVE BREAST CANCER

Increasing survival and QoL

Early detection

Accurate (clinico-pathological) characterization (NO “*one-fits-all*”)

Conservative surgical treatments:

- Lumpectomy / quadrantectomy + RT
- Mastectomy (subcutaneous, nipple-sparing)
- Breast reconstruction

Tailored systemic treatments

- Neo-adjuvant (pre-surgical)
- Adjuvant (prophylactic = hormonal, chemo, targeted)
- Metastatic setting
- Palliative